Patents Assigned to Nektar Therapeutics
-
Patent number: 11932726Abstract: The instant disclosure provides (among other things) improved methods of preparing fluorenyl-based polymeric reagents, methods of recovering and purifying such polymeric reagents, methods of reducing unwanted impurities in a fluorenyl-based polymeric reagent, fluorenyl-based polymeric reagents prepared by the methods described herein, and conjugates prepared by reaction with fluorenyl-based polymeric reagents prepared by the methods described herein.Type: GrantFiled: October 11, 2019Date of Patent: March 19, 2024Assignee: Nektar TherapeuticsInventors: Sean M. Culbertson, Samuel P. McManus, Antoni Kozlowski, Venkata Ravidnranadh Somu
-
Patent number: 11834553Abstract: Among other aspects, provided herein is a mixed-acid salt of a water-soluble polymer-drug conjugate, along with related methods of making and using the same. The mixed-salt acid salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding predominantly pure acid salt or free base forms of the polymer-drug conjugate. The mixed acid salt is reproducibly prepared and recovered, and provides surprising advantages over non-mixed acid salt forms of the water-soluble polymer drug conjugate.Type: GrantFiled: October 2, 2020Date of Patent: December 5, 2023Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Samuel P. McManus, Sachin Tipnis, Greg Lavaty, David Swallow, John R. Handley, Anthony G. Schaefer
-
Patent number: 11813241Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of taxane-based compounds and/or fluorinated forms thereof. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the taxane-based compound is achieved.Type: GrantFiled: September 7, 2018Date of Patent: November 14, 2023Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Timothy A. Riley, Samuel P. McManus
-
Patent number: 11744898Abstract: Provided are multi-arm polymer conjugates of Toll-Like Receptor (“TLR”) agonists such as TLR 7/8 agonists, as well as related compositions, and methods of making and using such conjugates. Exemplary conjugates are encompassed by Formula I: (I) or a pharmaceutically acceptable salt form thereof, where R, taken together with each Q, is a residue of a polyol, polythiol, or polyamine bearing from 3 to about 50 hydroxyl, thiol, or amino groups; each Q is a linker selected from oxygen, sulfur and —NH; each POLY is independently a water-soluble, non-peptidic polymer; each Xr is independently a linkage-containing spacer moiety; q is a positive integer from 3 to about 50; and each TLR 7/8 AG is a Toll-like receptor 7/8 agonist. Also provided is a method of administering to a patient having cancer (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) a Toll-like receptor agonist such as a conjugate as described above, as well as related compositions, kits and methods.Type: GrantFiled: January 10, 2018Date of Patent: September 5, 2023Assignee: Nektar TherapeuticsInventors: Zhongxu Ren, Neel K. Anand, Haiying Cai, Bo-Liang Deng, Bhalchandra V. Joshi, Jonathan Zalevsky, Takahiro Miyazaki, Saul Kivimae
-
Patent number: 11672776Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.Type: GrantFiled: July 3, 2018Date of Patent: June 13, 2023Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
-
Patent number: 11634540Abstract: Provided herein are polymeric ?-hydroxy aldehyde or ?-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the ?-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol.Type: GrantFiled: November 30, 2021Date of Patent: April 25, 2023Assignee: Nektar TherapeuticsInventors: Sean M. Culbertson, Xiaoming Shen, Antoni Kozlowski, Samuel P. McManus
-
Patent number: 11628205Abstract: The present disclosure provides conjugates comprising a Factor VIII moiety covalently attached via an oxime-containing linkage to a water-soluble polymer, such as for example, a polyethylene glycol polymer. Methods for preparing and for administering such conjugates, are also provided, as are water-soluble polymer oxyamine reagents useful for preparing the subject conjugates, among other things.Type: GrantFiled: July 21, 2017Date of Patent: April 18, 2023Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Dawei Sheng
-
Patent number: 11612662Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.Type: GrantFiled: June 25, 2020Date of Patent: March 28, 2023Assignee: Nektar TherapeuticsInventors: Lin Cheng, Jennifer Riggs-Sauthier
-
Patent number: 11464788Abstract: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.Type: GrantFiled: October 19, 2017Date of Patent: October 11, 2022Assignee: Nektar TherapeuticsInventors: Wen Zhang, Jennifer Riggs-Sauthier, J. Milton Harris, Michael D. Bentley
-
Patent number: 11446385Abstract: Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.Type: GrantFiled: April 6, 2020Date of Patent: September 20, 2022Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
-
Patent number: 11419943Abstract: The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.Type: GrantFiled: May 7, 2020Date of Patent: August 23, 2022Assignee: Nektar TherapeuticsInventors: Sean M. Culbertson, Antoni Kozlowski, Tony Drew Vinson
-
Patent number: 11406618Abstract: The invention relates to (among other things) polymer-des-ethyl sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over des-ethyl sunitinib in unconjugated form.Type: GrantFiled: January 9, 2019Date of Patent: August 9, 2022Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Sean M. Culbertson, Xiaoming Shen, Samuel P. McManus, Mark A. Wilson
-
Patent number: 11318164Abstract: Provided are methods and compositions directed towards the treatment of an individual having cancer by providing adoptive cell transfer therapy and administering to the individual a long-acting IL-2R?-biased agonist.Type: GrantFiled: March 1, 2018Date of Patent: May 3, 2022Assignee: Nektar TherapeuticsInventors: Deborah H. Charych, Antoni Ribas, Giulia Parisi
-
Patent number: 11266742Abstract: The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. The conjugates as well as the polymeric reagents used to form the conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided.Type: GrantFiled: May 19, 2020Date of Patent: March 8, 2022Assignee: Nektar TherapeuticsInventors: Michael D. Bentley, Sean M. Culbertson, Samuel P. McManus
-
Patent number: 11241415Abstract: Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.Type: GrantFiled: May 14, 2019Date of Patent: February 8, 2022Assignee: Nektar TherapeuticsInventors: Franco J. Duarte, Neel K. Anand, Wen Zhang, Pankaj Sharma, Devendrapratap Singh
-
Patent number: 11220575Abstract: Provided herein are polymeric ?-hydroxy aldehyde or ?-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the ?-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol.Type: GrantFiled: July 23, 2020Date of Patent: January 11, 2022Assignee: Nektar TherapeuticsInventors: Sean M. Culbertson, Xiaoming Shen, Antoni Kozlowski, Samuel P. McManus
-
Publication number: 20210386826Abstract: Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased cytokine agonist, and an anti-androgen or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 4, 2019Publication date: December 16, 2021Applicants: Pfizer Inc., MERCK PATENT GMBH, NEKTAR THERAPEUTICS, Astellas Pharma Inc.Inventors: Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Deborah Charych
-
Patent number: 11141465Abstract: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.Type: GrantFiled: May 17, 2018Date of Patent: October 12, 2021Assignee: Nektar TherapeuticsInventors: Mary J. Bossard, Michael D. Bentley, Ping Zhang
-
Patent number: 11129794Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.Type: GrantFiled: June 27, 2018Date of Patent: September 28, 2021Assignee: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
-
Publication number: 20210292415Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and a CD-122-biased agonist. In some embodiments, the tumor is derived from a melanoma, a renal cell carcinoma (RCC), a non-small cell lung carcinoma (NSCLC), a urothelial cancer (UC), a breast cancer, or any combination thereof.Type: ApplicationFiled: November 6, 2018Publication date: September 23, 2021Applicants: Bristol-Myers Squibb Company, Nektar TherapeuticsInventors: Wendy L. CLEMENS, Jonathan ZALEVSKY, Ute HOCH, Mary TAGLIAFERRI